E-mail updates

Sign up to receive updates from CGD:

  
Buy CGD books

Global Health Policy

« Africans Need Doctors, But They Need Health Even More | Main | Killing by Consensus: ACTs in Burkina Faso »

July 06, 2007

A Global Call for Informed Decisionmaking on HPV Vaccines

Posted by Jessica Pickett at 10:58 AM

HPV vaccines are the first of several new preventive technologies aimed at adolescent girls - an entirely new market that poses a series of unique policy and finance challenges to developing country governments and donors. As a result, decisions about HPV introduction have been so closely linked to the eventual availability of AIDS vaccines and microbicides that the conversation has largely shifted away from talk of cost-effectiveness and public health benefits (e.g. herd immunity) that are the traditional hallmarks of the global vaccine discourse and assumed the "health as a human right" rhetoric more often associated with the AIDS debate. Thus, within global health circles the discussion is generally couched as a question of how - not whether, when or under what circumstances - to introduce, finance, and deliver HPV vaccines throughout the developing world.

Now, a new coalition is formally adopting this charge. The Global Call to Stop Cervical Cancer, which was launched at the World YWCA International Women's Summit in Nairobi earlier today, "urges governments to prioritize cervical cancer in national development and health budgets, calls on multilateral agencies to ensure accelerated regulatory processes, appeals to international donors to ensure new vaccines and diagnostics are widely available, and calls upon industry to provide adequate supplies of new technologies at radically tiered prices." (See the press release for more details.) By launching the Global Call at a conference focused on HIV and AIDS, the organizers hope to encourage HIV activists and cervical cancer activists to learn from one another and share strategies to expand access to prevention and treatment.

The availability of this impressively effective vaccine seems to have magically brought down the walls of global health silos, but ultimately the adoption and uptake questions should be based on an assessment of the vaccine's own particular benefits (and costs) as an intervention in a given context, and not solely as a preparatory step for future products. One of the biggest hurdles - and current unknowns - is the price of the vaccines (set at $360 per course in the U.S.) and the costs and feasibility of programs to reach adolescents in developing countries. A recent study in the New England Journal of Medicine found that "for countries with a gross domestic product of less than $1,000 per capita, the per-dose cost may need to be as low as $1 to $2 to make vaccination both cost-effective and affordable." With that in mind, then, we need to be careful that we don't put the cart before the horse - or in this case, the advocacy bandwagon before the cost-effectiveness analyses, impact evaluations and other operational research activities that can best inform policymakers as they weigh this important decision. So I propose that the Global Call call for one more thing, too: the systematic generation of practical, credible knowledge that should inform country-by-country decisionmaking about whether introducing HPV vaccines makes sense.

Via Christine Gorman

Trackback Ping

TrackBack URL for this entry:
/mt/mt-tb.cgi/920

Comments

I wholeheartedly support the administration of HPV vaccines to adolescent and pre-sexually active females and I think it is an important step towards cervical cancer irradication. I do however agree that the cost of the vaccine will be a major hurdle for some economically challenged countries to overcome. As previously stated, some countries have a gross domestic product of less than $1,000 per capita so a $360 vaccine course will be far beyond its feasibility. I believe that some policies are needed that will ensure that impoverished countries will have access to the HPV vaccine or be provided with the vaccine at a reduced cost because what good will this breakthrough medicine serve if only those who are privileged to live in an economically sound country will reap the benefits. My hope is that organizations such as WHO and Global Call to Stop Cervical Cancer can partner with the manufactures of the HPV vaccine to ensure that every eligible female on the planet who desires to be vaccinated against cervial cancer, receives the opportunity to do so.

~Michelle

Posted by: Michelle Hurst at July 30, 2007 01:58 PM

Post a comment




Remember Me?

(you may use HTML tags for style)